Integrating MenB Immunization into Practice
Meningococcal serogroup B is the leading cause of invasive meningococcal disease (IMD) in Canada. Although this condition is relatively rare, IMD is associated with significant morbidity and mortality. Meningococcal serogroup B immunization can protect patients from this serious infection. In this program, Dr. Kirk Leifso provides expert IMD insight and discusses the role of immunization against this endemic infection.
This program is developed in collaboration with Queen’s University.
Credits for Family Medicine Specialists:
This 1-credit-per hour self-Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by Queen's University for up to 1 Mainpro+ credit. Session ID: 192934-001
Credits for Health Professionals:
This is an accredited learning activity which provided up to 1 hour of Continuing Education.
Kirk Leifso, MD, MSc, FRCPC, FAAP
Suni Boraston, MD, MHSc
Arawn Therrien, MSc, MD, CCFP
Dale Ziter, MD, CCFP, FCFP
Upon completion of this continuing education program, participants will be better able to:
- Review points regarding the epidemiology and impact of MenB in Canada
- Discuss the recommendations, benefits, and risks of the current MenB vaccine options
- Approach and recommend MenB immunization for appropriate patients